drugset
drugset / Trial / NCT01521767

Pharmacokinetics and Relative Bioavailability Study

NCT01521767 ↗

Phase 1 Completed 16 enrolled Viatris Inc.
RandomizedCrossoverOpen-labelOther

Summary

A Single-Dose Pharmacokinetics And Relative Bioavailability Study Of Tolterodine From Two Microspheres In Powder Blend Extended Release Formulations Compared To The Commercial Extended Release Capsules

Timeline

Start
2011-10
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Tolterodine Small molecule 4 mg —

Indications

overactive bladder